Next-Gen Creative Innovation for Life Sciences
Trivium Vet, an innovative player in veterinary medicine, has developed Felycin, a groundbreaking treatment for feline Hypertrophic Cardiomyopathy (HCM), a prevalent yet previously untreatable cardiac condition affecting 1 in 7 cats. With HCM's critical impact on feline health and the specialized nature of its diagnosis, Trivium Vet aimed to establish Felycin as a trusted brand within the veterinary community and among cat owners.
The Challenge
The primary challenge was to create a compelling brand and launch strategy for Felycin, which needed to resonate with veterinarians, veterinary cardiologists, and cat owners, educating them about this novel treatment in a market devoid of existing solutions for HCM.
Our Approach
To deliver a comprehensive branding exercise for Felycin, a groundbreaking treatment for feline Hypertrophic Cardiomyopathy (HCM) by Trivium Vet, our agency embarked on an in-depth exploration of the main brand, its stakeholders, and its target audience. We engaged closely with key stakeholders to understand their ambitions, motivations, and the critical impact of HCM on feline health. Our team conducted extensive research on the product, gaining a deep understanding of both veterinarians' and pet owners' perspectives. We facilitated brand workshops to align the vision and objectives, ensuring that everyone was on the same page regarding the brand's direction. Through these workshops, we fostered a collaborative environment that allowed us to capture the essence of Felycin and its mission. Our deliverables included a full suite of branding materials, from logo design to packaging and marketing communications. By immersing ourselves in the brand and its community, we created a cohesive and trusted identity for Felycin that resonates with both the veterinary community and cat owners, positioning it as a reliable solution for managing HCM.
